Rose Lectureship Will Focus on Managing Fluids in Septic AKI

Kathleen D. Liu
Search for other papers by Kathleen D. Liu in
Current site
Google Scholar
Full access

Kathleen D. Liu, MD, PhD, FASN

Citation: Kidney News 14, 10/11

The Burton D. Rose, MD, Endowed Lectureship will address “Fluid Management in Septic AKI: When, What Type, and How Much?” and will be held on Friday, November 4.

The speaker will be Kathleen D. Liu, MD, PhD, FASN, professor of medicine and anesthesia in the Divisions of Nephrology and Critical Care Medicine at the University of California San Francisco (UCSF), where she is also the medical director of the Medical Intensive Care Unit and the Apheresis/Hemodialysis Unit.

Dr. Liu's research has focused on acute kidney injury (AKI), acute respiratory distress syndrome, and critical care nephrology, with an emphasis on clinical trials. Currently, her main focus is on the predictive and pathogenetic role of biomarkers for both acute and chronic diseases with a long-term goal of identifying novel biomarkers of organ injury that may have predictive value for outcomes, as well as provide insight into disease pathogenesis. She also has a major interest in clinical trials in the intensive care unit, with a particular interest in acute lung injury and AKI.

Dr. Liu is a member of the National Institutes of Health Clinical Trials Network for the Prevention and Early Treatment of Acute Lung Injury and is involved in a US Department of Defense-funded clinical trial of mesenchymal stem cells for the treatment of trauma-associated acute respiratory distress syndrome. Her currently funded AKI research focuses on risk factors for AKI in collaboration with Kaiser Permanente of Northern California and on the pathways that mediate the relationship between AKI and subsequent cardiovascular disease in patients enrolled in the Assessment, Serial Evaluation, and Subsequent Sequelae of Acute Kidney Injury (ASSESS-AKI) study sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases.

Her service to professional organizations includes serving as a Steering Committee member of the ASN AKINow Initiative, as co-chair of a work group for the Kidney Disease: Improving Global Outcomes (KDIGO) AKI clinical practice guidelines, and as a member of the National Kidney Foundation Scientific Advisory Board. The Chinese American Society of Nephrology Young Investigator Award and an ASN Distinguished Leader Midcareer Award are among several awards that she has received.

Dr. Liu completed an MD/PhD program at UCSF. She then trained in internal medicine at Brigham and Women's Hospital in Boston and in nephrology and critical care at UCSF. She joined the UCSF faculty in 2006, where she has been since.